Stockholm, May 26, 2011 – NASDAQ OMX (NASDAQ:NDAQ) announces that Moberg Derma AB (ticker symbol: MOB), a small cap company within the Health Care sector, today starts trading of its shares on the main market of NASDAQ OMX Stockholm. Moberg Derma is the fourth company to list at NASDAQ OMX European markets in 2011.
Moberg Derma is a Swedish pharmaceutical company, which in five years has created an interesting product and project portfolio with annual sales potential exceeding SEK 3 billion at the distribution level. The portfolio covers approved and launched products to projects in the preclinical phase. Moberg Derma’s business idea is to develop patented topical pharmaceuticals for treatment of commonly prevailing diseases by using innovative drug delivery. Moberg Dermas products are based on proven compounds, which reduce time to market, development costs and risk. For more information visit: www.mobergderma.se.
Peter Wolpert, CEO and founder of Moberg Derma commented, “”Moberg Derma has developed faster than anticipated. We have rapidly gone from a development company to becoming a growth company. It is pleasing that investors have appreciated our focus on innovative development based on proven compounds and the value of having products on the market.”
Jenny Rosberg, Senior Vice President at NASDAQ OMX said, “We are excited to welcome Moberg Derma to NASDAQ OMX and our health care sector where we see a strong inflow of companies right now. We look forward to following Moberg Derma's growth and expansion in a listed environment and to support them with the increased investor awareness that comes with a main market listing.”